eli lilly retatrutide clinical trials Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Eli Lilly infiltrates anti-obesity market
Pay in 4 interest-free payments of $7.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28




























